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Background
HVTN 078 is a phase 1b clinical trial of heterologous
vector prime/boost vaccine regimens (NYVAC-B/rAd5
vs. rAd5/NYVAC-B) in healthy, HIV-1 uninfected, Ad5
seronegative adults. The rAd5 expressed a clade B Gag-
Pol fusion protein and secreted gp140s of HIV-1 strains
92RW020 (clade A), HxB2/Bal-V3/ V1V2 (clade B) and
97ZA012 (clade C). The NYVAC-B expressed a clade B
Gag-Pol-Nef polyprotein and the secreted gp120 of Bx08
(clade B). A total of 80 participants were randomized
into a placebo group (P) and four treatment groups: T1,
2x NYVAC-B/1x rAd5 (1010); T2, 1x rAd5 (108)/2x
NYVAC-B; T3, 1x rAd5 (109)/2x NYVAC-B; T4, 1x rAd5
(1010)/2x NYVAC-B.
Methods
Binding and neutralizing antibodies were assessed at 2
weeks post-final boosting. Neutralization was assessed
with tier 1 and tier 2 Env-pseudotyped viruses in TZM-bl
cells, and with tier 2 Env.IMC.LucR viruses in A3R5 cells.
Results
A dose effect for increasing anti-Env binding antibodies
was seen, with higher doses of rAd5 being optimal. For
neutralizing antibodies, positive response rates/median
titers across the treatment groups were highest against
MN.3 (69.3%/116) followed by SF162.LS (42.1%/54),
BaL.26 (18.4%/15.5), MW965.26 (14.5%/31) and Bx08.16
(11.8%/19.5). Five subjects neutralized all 5 tier 1 viruses,
5 subjects neutralized 4 viruses, 7 subjects neutralized 3
viruses, 14 subjects neutralized 2 viruses (MN.3 and
SF162.LS) and 18 subjects neutralized 1 virus (MN.3).
Aggregate magnitude-breadth scores across the tier 1
panel were strongest for T4 followed by T3, T1 and T2.
Differences were significant for T1 vs. T3 (p=0.048) and
T1 vs. T4 (p=0.004). Responses against tier 2 viruses
were weak and sporadic in the A3R5 assay and were
nearly absent in the TZM-bl assay.
Conclusion
A 1010 dose of rAd5 was superior to the two lower
doses of 109 and 108 for both binding and neutralizing
antibodies. At the highest rAd5 dose tested, rAd5/
NYVAC-B was superior to NYVAC-B/rAd5 for neutra-
lizing antibodies.
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